Dipeptidyl Peptidase 4 Inhibitors: Applications in Innate Immunity?

Roger Yazbek; Simone Jaenisch; Catherine Abbott

doi:10.1016/j.bcp.2021.114517

Dipeptidyl Peptidase 4 Inhibitors: Applications in Innate Immunity?

Roger Yazbek, Simone Jaenisch, Catherine Abbott

Research output: Contribution to journal › Review article › peer-review

22 Citations (Scopus)

Abstract

Dipeptidyl peptidase (DPP)-4 inhibitors are a class of orally available, small molecule inhibitors that prolong the insulinotropic activity of the incretin hormone glucagon-like peptide-1 (GLP-1) and are highly effective for the treatment of Type-2 diabetes. DPP4 can also cleave several immunoregulatory peptides including chemokines. Emerging evidence continues to implicate DPP4 inhibitors as immunomodulators, with recent findings suggesting DPP4 inhibitors modify specific aspects of innate immunity. This review summarises recent insights into how DPP4 inhibitors could be implicated in endothelial, neutrophil and monocyte/macrophage mediated immunity. Additionally, this review highlights additional avenues of research with DPP4 inhibitors in the context of the COVID-19 pandemic.

Original language	English
Article number	114517
Number of pages	10
Journal	Biochemical Pharmacology
Volume	188
DOIs	https://doi.org/10.1016/j.bcp.2021.114517
Publication status	Published - Jun 2021

Keywords

Dipeptidyl peptidase
DPP4 inhibitor
Sitagliptin
Immunity
Innate immunity
Neutrophil
Macrophage

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bcp.2021.114517Licence: In Copyright

Cite this

@article{16dae9f0021342c3be272ced586d9ad2,

title = "Dipeptidyl Peptidase 4 Inhibitors: Applications in Innate Immunity?",

abstract = "Dipeptidyl peptidase (DPP)-4 inhibitors are a class of orally available, small molecule inhibitors that prolong the insulinotropic activity of the incretin hormone glucagon-like peptide-1 (GLP-1) and are highly effective for the treatment of Type-2 diabetes. DPP4 can also cleave several immunoregulatory peptides including chemokines. Emerging evidence continues to implicate DPP4 inhibitors as immunomodulators, with recent findings suggesting DPP4 inhibitors modify specific aspects of innate immunity. This review summarises recent insights into how DPP4 inhibitors could be implicated in endothelial, neutrophil and monocyte/macrophage mediated immunity. Additionally, this review highlights additional avenues of research with DPP4 inhibitors in the context of the COVID-19 pandemic.",

keywords = "Dipeptidyl peptidase, DPP4 inhibitor, Sitagliptin, Immunity, Innate immunity, Neutrophil, Macrophage",

author = "Roger Yazbek and Simone Jaenisch and Catherine Abbott",

year = "2021",

month = jun,

doi = "10.1016/j.bcp.2021.114517",

language = "English",

volume = "188",

journal = "Biochemical Pharmacology",

issn = "0006-2952",

publisher = "Pergamon",

}

TY - JOUR

T1 - Dipeptidyl Peptidase 4 Inhibitors

T2 - Applications in Innate Immunity?

AU - Yazbek, Roger

AU - Jaenisch, Simone

AU - Abbott, Catherine

PY - 2021/6

Y1 - 2021/6

N2 - Dipeptidyl peptidase (DPP)-4 inhibitors are a class of orally available, small molecule inhibitors that prolong the insulinotropic activity of the incretin hormone glucagon-like peptide-1 (GLP-1) and are highly effective for the treatment of Type-2 diabetes. DPP4 can also cleave several immunoregulatory peptides including chemokines. Emerging evidence continues to implicate DPP4 inhibitors as immunomodulators, with recent findings suggesting DPP4 inhibitors modify specific aspects of innate immunity. This review summarises recent insights into how DPP4 inhibitors could be implicated in endothelial, neutrophil and monocyte/macrophage mediated immunity. Additionally, this review highlights additional avenues of research with DPP4 inhibitors in the context of the COVID-19 pandemic.

AB - Dipeptidyl peptidase (DPP)-4 inhibitors are a class of orally available, small molecule inhibitors that prolong the insulinotropic activity of the incretin hormone glucagon-like peptide-1 (GLP-1) and are highly effective for the treatment of Type-2 diabetes. DPP4 can also cleave several immunoregulatory peptides including chemokines. Emerging evidence continues to implicate DPP4 inhibitors as immunomodulators, with recent findings suggesting DPP4 inhibitors modify specific aspects of innate immunity. This review summarises recent insights into how DPP4 inhibitors could be implicated in endothelial, neutrophil and monocyte/macrophage mediated immunity. Additionally, this review highlights additional avenues of research with DPP4 inhibitors in the context of the COVID-19 pandemic.

KW - Dipeptidyl peptidase

KW - DPP4 inhibitor

KW - Sitagliptin

KW - Immunity

KW - Innate immunity

KW - Neutrophil

KW - Macrophage

UR - http://www.scopus.com/inward/record.url?scp=85104997469&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2021.114517

DO - 10.1016/j.bcp.2021.114517

M3 - Review article

C2 - 33722535

AN - SCOPUS:85104997469

SN - 0006-2952

VL - 188

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

M1 - 114517

ER -

Dipeptidyl Peptidase 4 Inhibitors: Applications in Innate Immunity?

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this